Project Narrative Endometrial cancer is the most common gynecologic cancer with a subset of serous-like tumors exhibiting evidence of homologous recombination (HR) DNA repair deficiency at the molecular level and phenotypically. This project will build on preliminary data to determine which molecular subtypes of endometrial cancer have the greatest sensitivity to inhibitors of poly (ADP ribose) polymerase (PARP) in patient-derived xenograft (PDX) models and fresh patient tumors. In addition, a novel combination of rucaparib plus pegylated SN38 (PLX038A) will be studied to build rationale for this combination patients with recurrent endometrial cancer.
|Effective start/end date||12/1/21 → 11/30/22|
- National Cancer Institute: $222,998.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.